Onconetix (ONCO) CEO David Allan White files initial Form 3 insider report

Rhea-AI Filing Summary

Onconetix, Inc. filed an initial insider ownership report for Chief Executive Officer David Allan White on Form 3. This filing establishes his status as an executive officer and subject to insider reporting rules, but it does not disclose any specific stock transactions or option exercises.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

White David Allan

(Last) (First) (Middle)

C/O ONCONETIX, INC.

201 E. FIFTH STREET, SUITE 1900

(Street)

CINCINNATI OHIO 45202

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Onconetix, Inc. [ ONCO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ David Allan White	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Onconetix (ONCO) Form 3 filing for David Allan White show?

The Form 3 identifies David Allan White as Chief Executive Officer of Onconetix and an insider subject to SEC reporting. It is an initial ownership statement and, in this case, does not list any specific stock transactions or derivative holdings.

Does the Onconetix (ONCO) Form 3 report any insider stock purchases or sales?

No, this Form 3 does not report any insider stock purchases, sales, or option exercises. It serves only to register David Allan White’s insider status at Onconetix as Chief Executive Officer without detailing individual share transactions.

Who is the insider named in the Onconetix (ONCO) Form 3?

The insider is David Allan White, who is listed as Chief Executive Officer of Onconetix. The filing confirms his officer role under SEC rules, triggering ongoing reporting obligations for future transactions in the company’s securities.

Why is Onconetix (ONCO) filing a Form 3 for its Chief Executive Officer?

Form 3 is required when someone becomes an officer, director, or major shareholder. Onconetix filed this Form 3 to record David Allan White’s status as Chief Executive Officer and establish his obligation to report future trades in company securities on Forms 4 and 5.

Does the Onconetix (ONCO) Form 3 include any derivative or option positions?

No, the insider data summary shows no derivative transactions or remaining derivative positions. The filing’s derivative-related fields are all zero, indicating no options, warrants, or similar instruments are reported for David Allan White in this initial statement.